Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention. METHODS: To compare prasugrel, a new thienopyridine, with clopidogrel, we randomly assigned 13,608 patients with moderate-to-high-risk acute coronary syndromes with scheduled percutaneous coronary intervention to receive prasugrel (a 60-mg loading dose and a 10-mg daily maintenance dose) or clopidogrel (a 300-mg loading dose and a 75-mg daily maintenance dose), for 6 to 15 months. The primary efficacy end point was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The key safety end point was major bleeding. RESULTS: The primary efficacy end point occurred in 12.1% of patients receiving clopidogrel and 9.9% of patients receiving prasugrel (hazard ratio for prasugrel vs. clopidogrel, 0.81; 95% confidence interval [CI], 0.73 to 0.90; P<0.001). We also found significant reductions in the prasugrel group in the rates of myocardial infarction (9.7% for clopidogrel vs. 7.4% for prasugrel; P<0.001), urgent target-vessel revascularization (3.7% vs. 2.5%; P<0.001), and stent thrombosis (2.4% vs. 1.1%; P<0.001). Major bleeding was observed in 2.4% of patients receiving prasugrel and in 1.8% of patients receiving clopidogrel (hazard ratio, 1.32; 95% CI, 1.03 to 1.68; P=0.03). Also greater in the prasugrel group was the rate of life-threatening bleeding (1.4% vs. 0.9%; P=0.01), including nonfatal bleeding (1.1% vs. 0.9%; hazard ratio, 1.25; P=0.23) and fatal bleeding (0.4% vs. 0.1%; P=0.002). CONCLUSIONS: In patients with acute coronary syndromes with scheduled percutaneous coronary intervention, prasugrel therapy was associated with significantly reduced rates of ischemic events, including stent thrombosis, but with an increased risk of major bleeding, including fatal bleeding. Overall mortality did not differ significantly between treatment groups. (ClinicalTrials.gov number, NCT00097591 [ClinicalTrials.gov].)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In patients with ACS undergoing PCI, 12 months' DAPT with low-dose ASA and prasugrel or ticagrelor was superior to DAPT with clopidogrel in the diabetes sub-group of the respective RCTs, with a benefit-risk profile similar to the overall trial populations (Supplementary data online, Tables S12-13).”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [310]
In the citing paper
“With prasugrel, the primary efficacy endpoint occurred in 9.9% of patients as compared with 12.1% receiving clopidogrel (HR 0.81, 95% CI 0.73-0.90;P , 0.001).The risk of major bleeding was increased with prasugrel.501”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [501]
In the citing paper
“With ticagrelor given for 12 months the composite endpoint of death from vascular causes, myocardial infarction, or stroke occurred in 9.8% as compared with 11.7% of those receiving clopidogrel (HR 0.84, 95% CI 0.77-0.92;P , 0.001).No significant difference in rate of major bleeding was found.501 -503”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [501]
In the citing paper
“In patients with ACS for whom an early invasive strategy is planned, dual antiplatelet therapy with a P2Y12 inhibitor (ticagrelor or prasugrel) added to aspirin was superior to clopidogrel and aspirin.”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [501]
Citations
Cites
Collaboration, A. T. (2002) · BMJ · doi:10.1136/bmj.324.7329.71 · Cited by 6,943
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Antman, E. M., Cohen, M., Bernink, P. J. L. M., McCabe, C. H., Horacek, T., Papuchis, G., Mautner, B., Corbalan, R., Radley, D., & Braunwald, E. (2000) · JAMA · doi:10.1001/jama.284.7.835 · Cited by 3,242
Self-citationSteinhubl, S. R., Berger, P. B., Mann III, J. T., Fry, E. T. A., DeLago, A., Wilmer, C., Topol, E. J., & for the CREDO Investigators (2002) · JAMA · doi:10.1001/jama.288.19.2411 · Cited by 3,078
Diener, H.-C., Bogousslavsky, J., Brass, L. M., Cimminiello, C., Csiba, L., Kaste, M., Leys, D., Matias-Guiu, J., & Rupprecht, H.-J. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16721-4 · Cited by 2,275
WRITING COMMITTEE MEMBERS, Smith, S. C., Feldman, T. E., Hirshfeld, J. W., Jacobs, A. K., Kern, M. J., King, S. B., Morrison, D. A., O’Neill, W. W., Schaff, H. V., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.170815 · Cited by 2,218
Self-citationSabatine, M. S., Cannon, C. P., Gibson, C. M., López-Sendón, J. L., Montalescot, G., Theroux, P., Claeys, M. J., Cools, F., Hill, K. A., Skene, A. M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050522 · Cited by 1,924
Self-citation(2005) · The Lancet · doi:10.1016/s0140-6736(05)67660-x · Cited by 1,858
Guidelines for Percutaneous Coronary Interventions
Silber, S., Albertsson, P., Avilés, F. F., Camici, P. G., Colombo, A., Hamm, C., Jørgensen, E., Marco, J., Nordrehaug, J.-E., Ruzyllo, W., et al. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi138 · Cited by 1,609
Stent Thrombosis in Randomized Clinical Trials of Drug-Eluting Stents
Mauri, L., Hsieh, W.-H., Massaro, J. M., Ho, K. K. L., D'Agostino, R., & Cutlip, D. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067731 · Cited by 1,441
Research works printed but not linked: 1
- Varenhorst C, 2007, Eur Heart J, 28, 189
Cited by
Items 301–400 of 1,004
Angiolillo, D. J., Capranzano, P., Goto, S., Aslam, M., Desai, B., Charlton, R. K., Suzuki, Y., Box, L. C., Shoemaker, S. B., Zenni, M. M., et al. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn287 · Cited by 200
Recent advances in the diagnosis and treatment of acute myocardial infarction
Reddy, K. (2015) · World Journal of Cardiology · doi:10.4330/wjc.v7.i5.243 · Cited by 200
Oldgren, J., Wallentin, L., Alexander, J. H., James, S., Jonelid, B., Steg, G., & Sundstrom, J. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht049 · Cited by 198
Berger, J. S., Frye, C. B., Harshaw, Q., Edwards, F. H., Steinhubl, S. R., & Becker, R. C. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.08.031 · Cited by 200
van Giezen, J. J. J., Sidaway, J., Glaves, P., Kirk, I., & Björkman, J.-A. (2012) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248411410883 · Cited by 198
“Dyspnea is unlikely to be associated with P2Y12 blockade itself, since increased blockade of the receptor by prasugrel did not seem to result in increased reporting of dyspnea.(8,33) Dyspnea is recognized as a side effect of intravenous adenosine administration in humans.”
BackgroundTepe, G., Bantleon, R., Brechtel, K., Schmehl, J., Zeller, T., Claussen, C. D., & Strobl, F. F. (2012) · European Radiology · doi:10.1007/s00330-012-2441-2 · Cited by 196
Cavender, M. A., & Sabatine, M. S. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61216-2 · Cited by 198
Pharmacogenomic Approach to Selecting Antiplatelet Therapy in Patients With Acute Coronary Syndromes
Notarangelo, F. M., Maglietta, G., Bevilacqua, P., Cereda, M., Merlini, P. A., Villani, G. Q., Moruzzi, P., Patrizi, G., Malagoli Tagliazucchi, G., Crocamo, A., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.02.029 · Cited by 196
“Given the TRITON-TIMI-38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel—Thrombolysis In Myocardial Infarction-38) trial findings and the exclusion criteria, prasugrel was not prescribed for: 1) patients whose coronary anatomy was unknown; 2) those at high bleeding…”
Self-citationCattaneo, M., Chassot, P.-G., Eichinger, S., Heymann, C. V., Hofmann, N., Rickli, H., Spannagl, M., Ziegler, B., Verheugt, F., Huber, K., et al. (2011) · Thrombosis and Haemostasis · doi:10.1160/th10-04-0217 · Cited by 196
“prasugrel or ticagrelor, can be expected in the near future (1, 2).”
BackgroundTeng, R., & Butler, K. (2010) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-009-0778-5 · Cited by 196
“with clopidogrel, this benefit was accompanied by an increased risk of major bleeding [19].”
BackgroundAssociation of MicroRNAs and YRNAs With Platelet Function
Kaudewitz, D., Skroblin, P., Bender, L. H., Barwari, T., Willeit, P., Pechlaner, R., Sunderland, N. P., Willeit, K., Morton, A. C., Armstrong, P. C., et al. (2016) · Circulation Research · doi:10.1161/circresaha.114.305663 · Cited by 195
Bittl, J. A., Baber, U., Bradley, S. M., & Wijeysundera, D. N. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.512 · Cited by 194
Palasubramaniam, J., Wang, X., & Peter, K. (2019) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.312578 · Cited by 192
Alexopoulos, D., Galati, A., Xanthopoulou, I., Mavronasiou, E., Kassimis, G., Theodoropoulos, K. C., Makris, G., Damelou, A., Tsigkas, G., Hahalis, G., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.03.050 · Cited by 193
The platelet P2Y12 receptor for adenosine diphosphate: congenital and drug-induced defects
Cattaneo, M. (2011) · Blood · doi:10.1182/blood-2010-08-263111 · Cited by 191
Paraneoplastic thrombocytosis: the secrets of tumor self-promotion
Lin, R. J., Afshar-Kharghan, V., & Schafer, A. I. (2014) · Blood · doi:10.1182/blood-2014-03-562538 · Cited by 188
Jneid, H., Addison, D., Bhatt, D. L., Fonarow, G. C., Gokak, S., Grady, K. L., Green, L. A., Heidenreich, P. A., Ho, P. M., Jurgens, C. Y., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.06.032 · Cited by 188
“Prasugrel should not be administered to patients with a history of prior stroke or transient ischemic attack.(116) (Class III, Level of Evidence: B) 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes11 1.”
BackgroundResultInfluentialChan, F. K. L., Goh, K.-L., Reddy, N., Fujimoto, K., Ho, K. Y., Hokimoto, S., Jeong, Y.-H., Kitazono, T., Lee, H. S., Mahachai, V., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-315131 · Cited by 188
Harold, J. G., Bass, T. A., Bashore, T. M., Brindis, R. G., Brush, J. E., Burke, J. A., Dehmer, G. J., Deychak, Y. A., Jneid, H., Jollis, J. G., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.002 · Cited by 187
De Luca, G., Damen, S. A., Camaro, C., Benit, E., Verdoia, M., Rasoul, S., Liew, H. B., Polad, J., Ahmad, W. A., Zambahari, R., et al. (2019) · EuroIntervention · doi:10.4244/eij-d-19-00539 · Cited by 187
Sibbing, D., Koch, W., Massberg, S., Byrne, R. A., Mehilli, J., Schulz, S., Mayer, K., Bernlochner, I., Schomig, A., & Kastrati, A. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr155 · Cited by 185
Steg, P. G., Mehta, S. R., Jukema, J. W., Lip, G. Y. H., Gibson, C. M., Kovar, F., Kala, P., Garcia-Hernandez, A., Renfurm, R. W., & Granger, C. B. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr334 · Cited by 186
Self-citationBaber, U., Dangas, G., Angiolillo, D. J., Cohen, D. J., Sharma, S. K., Nicolas, J., Briguori, C., Cha, J. Y., Collier, T., Dudek, D., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa670 · Cited by 185
Self-citationCardiovascular drug therapy in the elderly: benefits and challenges
Fleg, J. L., Aronow, W. S., & Frishman, W. H. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.162 · Cited by 186
“When combined with aspirin, prasugrel is related to higher rates of bleeding than clopidogrel in such patients and so is relatively contraindicated in the elderly, although it can be used in selected cases”
BackgroundGe, Z., Kan, J., Gao, X., Raza, A., Zhang, J.-J., Mohydin, B. S., Gao, F., Shao, Y., Wang, Y., Zeng, H., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00473-2 · Cited by 183
Jeong, Y.-H. (2014) · Current Cardiology Reports · doi:10.1007/s11886-014-0485-4 · Cited by 183
Angiolillo, D. J., Badimon, J. J., Saucedo, J. F., Frelinger, A. L., Michelson, A. D., Jakubowski, J. A., Zhu, B., Ojeh, C. K., Baker, B. A., & Effron, M. B. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehq494 · Cited by 183
Hochholzer, W., Wiviott, S. D., Antman, E. M., Contant, C. F., Guo, J., Giugliano, R. P., Dalby, A. J., Montalescot, G., & Braunwald, E. (2011) · Circulation · doi:10.1161/circulationaha.110.002683 · Cited by 183
Self-citationNikolaou, N. I., Arntz, H.-R., Bellou, A., Beygui, F., Bossaert, L. L., Cariou, A., & Danchin, N. (2015) · Resuscitation · doi:10.1016/j.resuscitation.2015.07.030 · Cited by 182
Jeong, Y.-H., Lee, S.-W., Choi, B.-R., Kim, I.-S., Seo, M.-K., Kwak, C. H., Hwang, J.-Y., & Park, S.-W. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.12.025 · Cited by 179
Capodanno, D., Mehran, R., Krucoff, M. W., Baber, U., Bhatt, D. L., Capranzano, P., Collet, J.-P., Cuisset, T., De Luca, G., De Luca, L., et al. (2023) · Circulation · doi:10.1161/circulationaha.123.064473 · Cited by 179
Self-citationAbraham, N. S., Hlatky, M. A., Antman, E. M., Bhatt, D. L., Bjorkman, D. J., Clark, C. B., Furberg, C. D., Johnson, D. A., Kahi, C. J., Laine, L., et al. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.445 · Cited by 179
Self-citationIntensifying Platelet Inhibition — Navigating between Scylla and Charybdis
Bhatt, D. L. (2007) · New England Journal of Medicine · doi:10.1056/nejme0706859 · Cited by 179
Switching P2Y12-receptor inhibitors in patients with coronary artery disease
Rollini, F., Franchi, F., & Angiolillo, D. J. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.113 · Cited by 177
Valgimigli, M., Tebaldi, M., Campo, G., Gambetti, S., Bristot, L., Monti, M., Parrinello, G., & Ferrari, R. (2012) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2012.01.006 · Cited by 173
“Previous comparative or placebo-controlled studies on GPIs (16,17) or oral P2Y12 blockers (18) have consistently hown the value of intensified platelet inhibition at the time f PCI to minimize ischemic complications.”
BackgroundChew, D. P., Scott, I. A., Cullen, L., French, J. K., Briffa, T. G., Tideman, P. A., Woodruffe, S., Kerr, A., Branagan, M., & Aylward, P. E. (2016) · Medical Journal of Australia · doi:10.5694/mja16.00368 · Cited by 173
Frelinger, A. L., Li, Y., Linden, M. D., Barnard, M. R., Fox, M. L., Christie, D. J., Furman, M. I., & Michelson, A. D. (2009) · Circulation · doi:10.1161/circulationaha.109.900589 · Cited by 171
Diagnosis and Management of Acute Coronary Syndrome: An Evidence-Based Update
Smith, J. N., Negrelli, J. M., Manek, M. B., Hawes, E. M., & Viera, A. J. (2015) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2015.02.140189 · Cited by 170
“Patients with a history of stroke or transient ischemic attack had net harm with the use of prasugrel, and therefore its use in these patients is contraindicated.(18) This trial was conducted in patients with moderate-to-high risk UA, NSTEMI, or STEMI who were referred for PCI, and prasugrel is U.”
MethodAn Aspirin-Free Versus Dual Antiplatelet Strategy for Coronary Stenting: STOPDAPT-3 Randomized Trial
Natsuaki, M., Watanabe, H., Morimoto, T., Yamamoto, K., Obayashi, Y., Nishikawa, R., Ando, K., Domei, T., Suwa, S., Ogita, M., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.066720 · Cited by 168
Morrow, D. A., Scirica, B. M., Fox, K. A. A., Berman, G., Strony, J., Veltri, E., Bonaca, M. P., Fish, P., McCabe, C. H., & Braunwald, E. (2009) · American Heart Journal · doi:10.1016/j.ahj.2009.06.027 · Cited by 172
Self-citationMauri, L., Kereiakes, D. J., Normand, S.-L. T., Wiviott, S. D., Cohen, D. J., Holmes, D. R., Bangalore, S., Cutlip, D. E., Pencina, M., & Massaro, J. M. (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.07.038 · Cited by 170
“The assumed MACCE and stent thrombosis rates are estimated from published data.(4,510,12,22) In powering the study for the primary end points under the Hochberg approach, the following are the treatment effect size assumptions used based on this published data:”
BackgroundMethodSelf-citationEffect of CYP2C19 Genotype on Ischemic Outcomes During Oral P2Y12 Inhibitor Therapy
Pereira, N. L., Rihal, C., Lennon, R., Marcus, G., Shrivastava, S., Bell, M. R., So, D., Geller, N., Goodman, S. G., Hasan, A., et al. (2021) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2021.01.024 · Cited by 166
Angiolillo, D. J., Saucedo, J. F., DeRaad, R., Frelinger, A. L., Gurbel, P. A., Costigan, T. M., Jakubowski, J. A., Ojeh, C. K., & Effron, M. B. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.02.072 · Cited by 169
Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents
LEVI, M., EERENBERG, E., & KAMPHUISEN, P. W. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04432.x · Cited by 170
Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus
Lorber, D. (2014) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s61438 · Cited by 168
“with prasugrel – Thrombolysis In Myocardial Infarction) 38 demonstrated that prasugrel produced a greater reduction in ischemic events than clopidogrel, but was associated with an increased risk of bleeding in patients with acute coronary syndrome undergoing percutaneous coronary intervention.(159) Interestingly, a su…”
Jneid, H., Addison, D., Bhatt, D. L., Fonarow, G. C., Gokak, S., Grady, K. L., Green, L. A., Heidenreich, P. A., Ho, P. M., Jurgens, C. Y., et al. (2017) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/hcq.0000000000000032 · Cited by 168
“Prasugrel should not be administered to patients with a history of prior stroke or transient ischemic attack.(116) (Class III, Level of Evidence: B) 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes11 1.”
BackgroundInfluentialHoenig, M. R., Doust, J., Aroney, C. N., & Scott, I. A. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004815.pub2 · Cited by 168
Morrow, D. A., Wiviott, S. D., White, H. D., Nicolau, J. C., Bramucci, E., Murphy, S. A., Bonaca, M. P., Ruff, C. T., Scirica, B. M., McCabe, C. H., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.833665 · Cited by 169
Self-citationBREIVIK, H., BANG, U., JALONEN, J., VIGFÚSSON, G., ALAHUHTA, S., & LAGERKRANSER, M. (2010) · Acta Anaesthesiologica Scandinavica · doi:10.1111/j.1399-6576.2009.02089.x · Cited by 166
“bination of antiplatelet drugs and LMWH as a causative factor.(83,84,110) Spontaneous SH in four patients treated with LMWH and ASA, one also”
BackgroundAntithrombotic Therapy in Patients With Chronic Kidney Disease
Capodanno, D., & Angiolillo, D. J. (2012) · Circulation · doi:10.1161/circulationaha.111.084996 · Cited by 165
Motovska, Z., Hlinomaz, O., Kala, P., Hromadka, M., Knot, J., Varvarovsky, I., Dusek, J., Jarkovsky, J., Miklik, R., Rokyta, R., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.008 · Cited by 165
Levine, G. N., Bates, E. R., Blankenship, J. C., Bailey, S. R., Bittl, J. A., Cercek, B., Chambers, C. E., Ellis, S. G., Guyton, R. A., Hollenberg, S. M., et al. (2012) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.23438 · Cited by 166
“In patients receiving DES for a non-ACS indication, clopidogrel 75 mg daily should be given for at least 12 months if patients are not at high risk of bleeding (107, 232, 286).”
InfluentialRadico, F., Zimarino, M., Fulgenzi, F., Ricci, F., Di Nicola, M., Jespersen, L., Chang, S. M., Humphries, K. H., Marzilli, M., & De Caterina, R. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy185 · Cited by 165
Bonaca, M. P., Wiviott, S. D., Braunwald, E., Murphy, S. A., Ruff, C. T., Antman, E. M., & Morrow, D. A. (2012) · Circulation · doi:10.1161/circulationaha.111.041160 · Cited by 164
Self-citation(2011) · Heart, Lung and Circulation · doi:10.1016/j.hlc.2011.03.008 · Cited by 163
“The TRITON-TIMI 38 study reported that, compared with clopidogrel, prasugrel was associated with a reduction in the combined endpoint of cardiovascular death, MI or stroke in patients with ACS scheduled for PCI, but at the cost of an increase in the rate of major bleeding [33].”
MethodF. Piepoli, M. (2017) · International Journal of Behavioral Medicine · doi:10.1007/s12529-016-9583-6 · Cited by 162
“Following an episode of ACS, dual antiplatelet therapy given for a period of 12 months is a standard treatment based on results from the CURE [455], TRITON [456] and PLATO [457] studies, whereas no clinical studies support the use of prasugrel and ticagrelor in patients with stable CAD.”
Storey, R. F., James, S. K., Siegbahn, A., Varenhorst, C., Held, C., Ycas, J., Husted, S. E., Cannon, C. P., Becker, R. C., Steg, P. G., et al. (2014) · Platelets · doi:10.3109/09537104.2013.842965 · Cited by 162
Bleeding avoidance strategies in percutaneous coronary intervention
Capodanno, D., Bhatt, D. L., Gibson, C. M., James, S., Kimura, T., Mehran, R., Rao, S. V., Steg, P. G., Urban, P., Valgimigli, M., et al. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00598-1 · Cited by 162
Self-citationSahlén, A., Varenhorst, C., Lagerqvist, B., Renlund, H., Omerovic, E., Erlinge, D., Wallentin, L., James, S. K., & Jernberg, T. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw284 · Cited by 161
Periprocedural Myocardial Infarction: Prevalence, Prognosis, and Prevention
Lansky, A. J., & Stone, G. W. (2010) · Circulation: Cardiovascular Interventions · doi:10.1161/circinterventions.110.959080 · Cited by 160
Sumaya, W., Wallentin, L., James, S. K., Siegbahn, A., Gabrysch, K., Bertilsson, M., Himmelmann, A., Ajjan, R. A., & Storey, R. F. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy013 · Cited by 160
Sex differences in mechanisms, presentation and management of ischaemic heart disease
Crea, F., Battipaglia, I., & Andreotti, F. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.04.802 · Cited by 159
Angiolillo, D. J., Schneider, D. J., Bhatt, D. L., French, W. J., Price, M. J., Saucedo, J. F., Shaburishvili, T., Huber, K., Prats, J., Liu, T., et al. (2012) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-012-0737-3 · Cited by 159
Introduction to the Ninth Edition
Guyatt, G. H., Akl, E. A., Crowther, M., Schünemann, H. J., Gutterman, D. D., & Lewis, S. Z. (2012) · Chest · doi:10.1378/chest.11-2286 · Cited by 159
Fifi, J. T., Brockington, C., Narang, J., Leesch, W., Ewing, S. L., Bennet, H., Berenstein, A., & Chong, J. Y. (2012) · American Journal of Neuroradiology · doi:10.3174/ajnr.a3405 · Cited by 158
“Several studies have shown increased risk of hemorrhage on more potent antiplatelet therapy in patients with stroke.(28,29) Our data appear to support using a higher threshold for clopidogrel resistance in neurovascular patients.”
BackgroundAriotti, S., Adamo, M., Costa, F., Patialiakas, A., Briguori, C., Thury, A., Colangelo, S., Campo, G., Tebaldi, M., Ungi, I., et al. (2016) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2015.11.015 · Cited by 158
Savonitto, S., Ferri, L. A., Piatti, L., Grosseto, D., Piovaccari, G., Morici, N., Bossi, I., Sganzerla, P., Tortorella, G., Cacucci, M., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.032180 · Cited by 159
The Platelet Response to Tissue Injury
Eisinger, F., Patzelt, J., & Langer, H. F. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00317 · Cited by 154
Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An Update
Teng, R. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0290-2 · Cited by 177
“However, as shown in TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel–Thrombolysis in Myocardial Infarction 38), these positive effects are accompanied by an increase in the rate of major bleeding [13].”
MethodCombining Antiplatelet and Anticoagulant Therapies
Holmes, D. R., Kereiakes, D. J., Kleiman, N. S., Moliterno, D. J., Patti, G., & Grines, C. L. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.03.044 · Cited by 164
Rokos, I. C., French, W. J., Mattu, A., Nichol, G., Farkouh, M. E., Reiffel, J. A., & Stone, G. W. (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.08.011 · Cited by 154
Galli, M., Benenati, S., Franchi, F., Rollini, F., Capodanno, D., Biondi‐Zoccai, G., Vescovo, G. M., Cavallari, L. H., Bikdeli, B., ten Berg, J. M., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab836 · Cited by 172
Self-citationCuisset, T., Frère, C., Quilici, J., Morange, P., Mouret, J.-P., Bali, L., Moro, P.-J., Lambert, M., Alessi, M., & Bonnet, J. (2008) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2008.08.018 · Cited by 152
Fokkema, M. L., Vlaar, P. J. J., Svilaas, T., Vogelzang, M., Amo, D., Diercks, G. F. H., Suurmeijer, A. J. H., & Zijlstra, F. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehp033 · Cited by 150
Aspirin and P2Y12 Inhibitors in platelet-mediated activation of neutrophils and monocytes
Schrottmaier, W. C., Kral-Pointner, J. B., Badrnya, S., & Assinger, A. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-11-0943 · Cited by 160
“However, the benefits regarding ischaemic endpoints are balanced by increased risk of major bleeding in prasugrel compared to clopidogrel treated patients (74).”
BackgroundRocca, B., Fox, K. A. A., Ajjan, R., Andreotti, F., Baigent, C., Collet, J., Grove, E. L., Halvorsen, S., Huber, K., Morais, J., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy066 · Cited by 157
Ticagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary Stenting
Franzone, A., McFadden, E. P., Leonardi, S., Piccolo, R., Vranckx, P., Serruys, P. W. J. C., Benit, E., Liebetrau, C., Janssens, L., Ferrario, M., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.08.1038 · Cited by 163
Response Variability to P2Y12 Receptor Inhibitors
Siller-Matula, J. M., Trenk, D., Schrör, K., Gawaz, M., Kristensen, S. D., Storey, R. F., & Huber, K. (2013) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2013.06.011 · Cited by 165
“In the TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel–Thrombolysis in Myocardial Infarction 38) trial, prasugrel reduced ischemic events by 19% compared with clopidogrel (110).”
BackgroundAdverse Drug Events as a Cause of Hospitalization in Older Adults
Salvi, F., Marchetti, A., D’Angelo, F., Boemi, M., Lattanzio, F., & Cherubini, A. (2012) · Drug Safety · doi:10.1007/bf03319101 · Cited by 177
Goto, S., Ogawa, H., Takeuchi, M., Flather, M. D., Bhatt, D. L., & on behalf of the J-LANCELOT (Japanese-Lesson from Antagonizing the Cellular Effect of Thrombin) Investigators (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq320 · Cited by 146
“The current standard of care for ACS patients is dual antiplatelet therapy with aspirin and clopidogrel, although studies show that newer P2Y12 inhibitors, including prasugrel and ticagrelor, are more effective than clopidogrel.(26,27) Limitations of clopidogrel include relatively slow onset of effect, low PAI in many…”
BackgroundOzaki, Y., Hara, H., Onuma, Y., Katagiri, Y., Amano, T., Kobayashi, Y., Muramatsu, T., Ishii, H., Kozuma, K., Tanaka, N., et al. (2022) · Cardiovascular Intervention and Therapeutics · doi:10.1007/s12928-021-00829-9 · Cited by 164
“Prasugrel and ticagrelor reduce ischemic events and mortality in ACS patients compared to clopidogrel and are recommended by current guidelines [20, 21, 51].”
BackgroundPharmacology and Clinical Development of Factor XI Inhibitors
Greco, A., Laudani, C., Spagnolo, M., Agnello, F. G., Faro, D. C., Finocchiaro, S., Legnazzi, M., Mauro, M. S., Mazzone, P. M., Occhipinti, G., et al. (2023) · Circulation · doi:10.1161/circulationaha.122.062353 · Cited by 170
The role of monocytes in thrombotic disorders
Lip, G. Y. H., & Shantsila, E. (2009) · Thrombosis and Haemostasis · doi:10.1160/th09-01-0023 · Cited by 146
“Unfortunately, the development of novel, more potent antithrombotic therapies directed to inhibit activity of platelets or coagulation factors are limited by the correspondently increasing risk of bleeding complications (5).”
BackgroundFerri, N., Corsini, A., & Bellosta, S. (2013) · Drugs · doi:10.1007/s40265-013-0126-z · Cited by 154
“ticagrelor-treated patients than in clopidogrel-treated patients undergoing CABG [127, 168].”
BackgroundMethodInfluentialPlatelet-derived S100 family member myeloid-related protein-14 regulates thrombosis
Wang, Y., Fang, C., Gao, H., Bilodeau, M. L., Zhang, Z., Croce, K., Liu, S., Morooka, T., Sakuma, M., Nakajima, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70966 · Cited by 157
“…apixaban) agents are being developed on the basis of superior efficacy, these therapeutic advances are associated with a 25% to 30% increase in the rate of bleeding (prasugrel, ticagrelor, apixaban) or transfusion (rivaroxaban, apixaban) in the treatment of acute coronary syndromes (60–62).”
Butler, K. A., & Teng, R. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03669.x · Cited by 145
Levine, G. N., Bates, E., Blankenship, J. C., Bailey, S. R., Bittl, J. A., Cercek, B., Chambers, C. E., Ellis, S. G., Guyton, R. A., Hollenberg, S. M., et al. (2011) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.23390 · Cited by 406
“Continuation of clopidogrel, prasugrel, or ticagrelor beyond 12 months may be considered in patients undergoing placement of DES (567, 568).”
InfluentialNavarese, E. P., Khan, S. U., Kołodziejczak, M., Kubica, J., Buccheri, S., Cannon, C. P., Gurbel, P. A., De Servi, S., Budaj, A., Bartorelli, A., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.046786 · Cited by 146
“…mo June 27, 2008 to September 12, 2011 Prasugrel 10 mg od 4663 ACS without revascularization Clopidogrel 75 mg od 4663 [TRITON-TIMI 38]10 Wiviott et al 2007 NEJM [NCT00097591] 15 mo November 2004 to January 2007 Prasugrel 10 mg od 6813 ACS with scheduled PCI Clopidogrel 75 mg od…”
MethodSidéris, G., Cohen, R., Meuleman, C., Sollier, C. B. D., Barthélémy, O., Henry, P., Lim, P., Beygui, F., Collet, J., Marshall, D. A., et al. (2009) · Thrombosis and Haemostasis · doi:10.1160/th09-07-0482 · Cited by 146
Self-citationAngiolillo, D. J. (2009) · Diabetes Care · doi:10.2337/dc08-2064 · Cited by 160
“Encouraging clinical outcome data from large-scale phase III testing is available for prasugrel (61).”
BackgroundO’Donoghue, M. L., Murphy, S. A., & Sabatine, M. S. (2020) · Circulation · doi:10.1161/circulationaha.120.046251 · Cited by 145
Self-citationBentzon, J. F., Daemen, M., Falk, E., Garcia-Garcia, H. M., Herrmann, J., Hoefer, I., Jukema, J. W., Krams, R., Kwak, B. R., Marx, N., et al. (2011) · Thrombosis and Haemostasis · doi:10.1160/th10-12-0784 · Cited by 143
“The positive effects of prasugrel (TRITON) (194) and ticagrelor (PLATO) (195) on CVD events were even greater.”
BackgroundKukreja, N., Onuma, Y., García‐García, H. M., Daemen, J., van Domburg, R., & Serruys, P. W. J. C. (2009) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2009.04.003 · Cited by 143
Mahoney, E. M., Wang, K., Arnold, S. V., Proskorovsky, I., Wiviott, S. D., Antman, E. M., D, E. B. M., & Cohen, D. J. (2009) · Circulation · doi:10.1161/circulationaha.109.900704 · Cited by 143
Self-citationProton Pump Inhibitor and Clopidogrel Interaction: Fact or Fiction?
Laine, L., & Hennekens, C. H. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.638 · Cited by 142
“Although prasugrel is more effective than clopidogrel in reducing CV events in patients with moderate-to-high risk acute coronary syndromes, its use is currently recommended only in selected patients because it causes significantly more major bleeding than clopidogrel (”
BackgroundRossini, R., Musumeci, G., Visconti, L. O., Bramucci, E., Castiglioni, B., Servi, S. D., Lettieri, C., Lettino, M., Piccaluga, E., Savonitto, S., et al. (2014) · EuroIntervention · doi:10.4244/eijv10i1a8 · Cited by 152
Halvorsen, S., Storey, R. F., Rocca, B., Sibbing, D., ten Berg, J. M., Grove, E. L., Weiss, T. W., Collet, J., Andreotti, F., Gulba, D. C., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw454 · Cited by 166
Lee, D. H., Arat, A., Morsi, H., Shaltoni, H. M., Harris, J. R., & Mawad, M. E. (2008) · American Journal of Neuroradiology · doi:10.3174/ajnr.a1070 · Cited by 142
“A new antiplatelet agent (prasugrel), which is said to have more reliable antiplatelet action, is now in clinical trial.(27) Currently, we are aware of the variability of the antiplatelet action of clopidogrel manifested by occurrence of in-stent thrombosis in the neurointerventional arena.”
BackgroundDrug Treatment of Acute Ischemic Stroke
Bansal, S., Sangha, K. S., & Khatri, P. (2013) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-013-0007-6 · Cited by 149
“lor, and prasugrel have been studied in recent trials, although none were tested in AIS patients [66, 67].”
Sabatine, M. S., Antman, E. M., Widimský, P., Ebrahim, I. O., Kiss, R. G., Saaiman, A., Polášek, R., Contant, C. F., McCabe, C. H., & Braunwald, E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61454-9 · Cited by 144
Self-citation
Metadata
- Authors
- Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., Riesmeyer, J., Weerakkody, G., Gibson, C. M., & Antman, E. M.
- Affiliations
- Brigham and Women's Hospital (US)
- Inserm (FR)
- Bikur Cholim Hospital (IL)
- Universitäts-Herzzentrum Freiburg-Bad Krozingen (DE)
- Ospedale di Parma (IT)
- Eli Lilly (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11-15
- Volume
- 357
- Issue
- 20
- Pages
- 2001-2015
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2169387542
- Cited by
- 6,790
- References
- 40
- Citations by year
- 2026: 162 · 2025: 202 · 2024: 187 · 2023: 265 · 2022: 309 · 2021: 326 · 2020: 339 · 2019: 361 · 2018: 389 · 2017: 418 · 2016: 419 · 2015: 465 · 2014: 448 · 2013: 502 · 2012: 507
- FWCI
- 238.04
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- prasugrel, clopidogrel, acute coronary syndrome, percutaneous coronary intervention, dual antiplatelet therapy, thienopyridines, major bleeding, stent thrombosis, myocardial infarction, target vessel revascularization, cardiovascular mortality, bleeding risk stratification, bleeding risk score
- MeSH terms
- Prasugrel Hydrochloride, Clopidogrel, Aged, Aspirin, Double-Blind Method, Drug Therapy, Combination, Female, Hemorrhage, Humans, Male, Middle Aged, Myocardial Infarction, Piperazines, Platelet Aggregation Inhibitors, Prodrugs, Thiophenes, Thrombosis, Ticlopidine, Angioplasty, Balloon, Coronary, Stroke, Kaplan-Meier Estimate, Acute Coronary Syndrome, Purinergic P2 Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.